Rochester Medical Corporation (Form: 8-K)

Rochester Medical Corporation (NASDAQ: ROCM) today announced operating results for its first quarter ended December 31, 2004.

The Company reported sales of $3,665,000 for the quarter compared to $3,348,000 for the first quarter of last year. It also reported a net income of $122,000 or $.02 per share for the quarter compared to $64,000 or $.01 per share for the first quarter of last year. The 9% increase in revenues resulted from increased sales of Rochester Medical^® branded products and increased sales of Private Label products. The 91% increase in earnings resulted from higher contribution from increased sales partially offset by increased operational expenses primarily related to Marketing and Selling and General Administrative activities.

Commenting on the quarter, Company CEO and President Anthony J. Conway said, “The first quarter was in line with our expectations. I am pleased with the overall growth in sales of our Rochester Medical branded products which increased 16% over the same period last year. Private Label sales increased a modest 4%.

“We remain very pleased with the market acceptance of our advanced products, and we expect further growth as we introduce important new products this quarter and throughout the year.”

The immediately preceding statement contains forward-looking statements that involve risks and uncertainties, including the uncertainty of gaining acceptance of the anti- infection catheters and hydrophilic catheters in the marketplace, the uncertainty of new product introductions, the uncertainty of gaining new strategic relationships, the uncertainty of timing of private label sales revenues (particularly international customers), FDA and other regulatory review and response times, as well as other risk factors listed from time to time in the Company’s SEC reports and filings, including, without limitation, the section entitled “Risk Factors” in the Company’s Annual report on Form 10-K (Part II, Item 6) for the year ended September 30, 2004.

Rochester Medical Corporation develops, manufactures, and markets latex-free disposable medical catheters and devices for urological and continence care applications. The Company markets under its own Rochester Medical brand and under private label arrangements.

For further information, please contact Anthony J. Conway, President and Chief Executive Officer of Rochester Medical Corporation at (507) 533-9600. More information about Rochester Medical is available on its website at http://www.rocm.com.

Rochester Medical has scheduled a conference call today at 4:00 p.m., C.S.T. regarding this announcement. The call is being webcast by Thompson/CCBN and can be accessed at Rochester Medical’s website www.rocm.com. To listen live to the conference call via telephone, call:


Rochester Medical Corporation
Press Release - F05 First Quarter
	Condensed Balance Sheets
		December 31,		September 30,
		2004		2004
	Assets
Current Assets
Cash and equivalents		$	367,168	$	620,441
Marketable securities			5,263,049		5,251,763
Accounts receivable			2,380,077		2,631,188
Inventories			4,400,576		3,945,313
Prepaid expenses and other assets			385,377		273,229

Total current assets			12,796,247		12,721,934
Property and equipment			8,316,969		8,442,427
Intangible assets			229,607		219,296

		$	21,342,823	$	21,383,657

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	655,263	$	778,766
Accrued expenses			564,661		595,145
Short-term debt			34,000		34,000
Current Maturities of Capital Leases			38,143		37,611
Deferred revenue			157,143		157,143

Total current liabilities			1,449,210		1,602,665
Long-term debt
Long term debt			68,000		68,000
Capital leases, less current portion			94,077		103,814
Deferred revenue			682,143		721,429

Total long term debt			844,220		893,243
Stockholders' equity			19,049,393		18,887,749

		$	21,342,823	$	21,383,657


Rochester Medical Corporation
Press Release - F05 First Quarter
	Summary Statements Of Operations
		Three months ended
		December 31,
		2004			2003
Sales		$	3,665,272		$	3,348,474
Cost of sales			2,267,278			2,153,705

Gross profit			1,397,994			1,194,769
Gross profit %			38	%		36	%
Costs and expense:
Marketing and selling			570,538			510,665
Research and development			196,730			176,771
General and administrative			537,028			456,581

Total operating expenses			1,304,296			1,144,017

Income from operations			93,698			50,752
Other income
Interest income			28,298			12,836

Net Income		$	121,996		$	63,588

Earnings per common share — Basic		$	0.02		$	0.01

Earnings per common share — Diluted		$	0.02		$	0.01

Shares in per share
computation Basic			5,448,287			5,427,709

Shares in per share
computation Diluted			5,683,360			5,725,215


Minnesota	0-18933	41-1613227
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

One Rochester Medical Drive, Stewartville, Minnesota		55976
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


	Rochester Medical Corporation

January 20, 2005	By:	David A. Jonas

		Name: David A. Jonas
		Title: Chief Financial Officer


Exhibit No.		Description

99.1		Press Release, dated January 18, 2005, issued by Rochester Medical Corporation


Date of Report (Date of Earliest Event Reported):		January 18, 2005


Registrant’s telephone number, including area code:		507-533-9600